ABION to Collaborate with US Government on ABN101 Development... "Pipeline Valued at 700 Billion KRW"

Abion announced on the 4th that it is promoting the joint development of the respiratory virus treatment ABN101 with a U.S. government agency.

ABN101 is Abion's pipeline being developed as a broad-spectrum antiviral drug. As a next-generation interferon beta, it improves the material stability of the existing natural interferon beta and increases production yield by more than 500 times, enabling research and production of various formulations at an economical cost. In particular, it has been developed in a dry powder formulation that is advantageous for transportation, storage, and administration, and it has been confirmed that its biological activity increased more than threefold compared to the natural form.

To promote joint development with the U.S. government agency, the company also participated last month in the Tech Watch Forum held in the U.S., where it presented the antiviral efficacy of ABN101 against respiratory viruses in vivo. The Tech Watch Forum is an event hosted by the U.S. Defense Threat Reduction Agency (DTRA) and the Joint Science and Technology Office (JSTO), contributing to the promotion of cooperation among industry, academia, and U.S. federal government agencies.

A company official stated, “We will accelerate the development of the pipeline to protect soldiers and civilians from various viral threats such as influenza and COVID-19,” adding, “According to the recent evaluation by the U.S.-based specialized assessment agency K, the pipeline value of ABN101 exceeds 700 billion KRW.”